Management will host its third quarter 2019 conference call on Monday, November 11, 2019 to provide a corporate update and review the Company’s poster presentations from SITC HOLON, Israel, Oct. 2, 2019 /PRNewswire/ — October 2, 2019 – Compugen...
Study evaluates clinical utility of 68Ga THP-PSMA PET/CT imaging in men with newly diagnosed and recurrent prostate cancer LONDON and BOSTON, Oct. 2, 2019 /PRNewswire/ — Theragnostics, which is developing innovative radiopharmaceuticals to improve cancer...
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today FDA clearance to initiate enrollment in the...
Silicon Valley Bank and Oxford Finance to further strengthen our cash position.” EQUALISE is a Phase 1b multiple ascending dose trial that is evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD), and clinical activity of itolizumab in...
The Pitt Hopkins Research Foundation announces its first-ever human clinical trial to attempt to eradicate the severe gastrointestinal effects of Pitt-Hopkins syndrome (PTHS), a rare disorder caused by a mutation of the TCF4 gene (18 chromosome) and often classified...
Equillium, Inc. (NASDAQ: EQ) today announced it has initiated the EQUALISE Phase 1b clinical trial of itolizumab (EQ001) in patients with lupus nephritis and provided an update on its ongoing clinical programs. Additionally, Equillium announced an agreement with...
Email
Text